BRIEF—Theravance and Mylan win US approval for Yupelri

Theravance Biopharma and Mylan have won US approval for Yupelri (revefenacin) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

The long-acting muscarinic antagonist is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the USA.

The firms say they expect to launch this year. COPD is the third leading cause of death and the fourth leading cause of hospital readmissions in the USA, affecting approximately 16 million people.